DRTS
- Alpha Tau Medical Ltd.
()
Overview
Company Summary
Alpha Tau Medical Ltd. (DRTS) is a company focused on developing and providing an innovative cancer treatment technology called Diffusing Alpha-emitters Radiation Therapy (DART). DART utilizes alpha radiation to destroy cancer cells while minimizing damage to healthy surrounding tissues, offering a potential breakthrough in cancer treatment.
The company's primary objective is to provide a non-invasive and highly targeted treatment alternative for various types of solid tumors, including breast, prostate, brain, and bone cancer. In contrast to conventional radiation therapies, which use beta or gamma radiation, DART employs alpha radiation, which has shorter range and higher energy. This allows for a more precise and localized delivery of radiation, limiting potential side effects and improving treatment outcomes.
At the core of Alpha Tau Medical's technology is the alpha-emitting radioisotope called Radium-224. Radium-224 is attached to nano-particles called Actinium-225, forming a highly potent radioactive substance. These nano-particles are infused into a patient's bloodstream, where they naturally accumulate in the tumor. Once localized, the nanoparticles release alpha radiation, selectively destroying cancerous cells while sparing healthy tissues nearby.
Alpha Tau Medical aims to address the limitations of conventional cancer treatments, such as surgery, chemotherapy, and external beam radiation therapy. The company's technology has shown promising results in pre-clinical and early clinical trials, demonstrating reduced side effects and improved tumor control rates.
Through its ongoing research and development efforts, Alpha Tau Medical strives to further enhance the effectiveness and accessibility of DART. The company collaborates with leading medical centers, clinicians, and researchers globally to conduct clinical trials, gain regulatory approvals, and establish partnerships for commercialization.
In summary, Alpha Tau Medical Ltd. (DRTS) is a healthcare company that specializes in developing and providing a state-of-the-art cancer treatment known as Diffusing Alpha-emitters Radiation Therapy (DART). Their innovative approach harnesses the power of alpha radiation to target and destroy cancer cells, offering potential advantages over existing treatment options.